Table 5. Univariate analysis of variables for prediction of SVR in GT2 and GT3.

	Genotype 2					Genotype 3
Baseline variables	p	OR	95% CI for OR *		N	p	OR	95% CI for OR *		N
Gender	0.805				391	0.156				1956
Age ≤45 vs.>45 years	0.842				391	0.014	0.781	0.642	0.950	1956
BMI	0.843				391	0.364				1956
Subtype of HCV genotype	0.381				224	0.753				1332
Duration of infection (years)	0.910				332	0.800				1743
HCV-RNA ≤400,000 vs.>400,000 IU/ml	0.458				390	0.045	0.832	0.695	0.996	1935
Psychiatric co-morbidity	0.972				391	0.022	0.754	0.591	0.960	1956
HIV co-infection	0.752				391	0.558				1956
HBV co-infection	0.406				391	0.166				1956
Current drug use	0.388				391	0.063				1956
LDL cholesterol ≤85 vs.>85 mg/dl	0.308				120	0.000	2.073	1.456	2.951	532
Cholesterol ≤130 vs.>130 mg/dl	0.332				220	0.000	1.838	1.360	2.483	1037
Triglycerides (mg/dl)	0.962				210	0.564				945
Serum ferritin (µg/l)	0.075				150	0.206				657
Prothrombine time (%)	0.007	1.032	1.009	1.055	245	0.138				1155
APRI score <0.5; 0.5-≤1.5; 1.5-≤2 #	0.050	0.783	0.613	1.000	346	0.000	0.764	0.689	0.846	1780
γ-GT> vs. ≤3-times ULN	0.017	0.392	0.182	0.844	370	0.000	0.480	0.347	0.663	1872
Variables under treatment
RVR	0.000	3.759	2.004	7.052	195	0.000	2.900	2.210	3.803	963
Duration of therapy <22 weeks - 22–26 weeks ->26 weeks	0.247				359	0.732				1643**
Change in dose PEG-interferon	0.326				391	0.140				1953
RBV starting dose (mg/kg body weight)	0.002	1.127	1.046	1.213	390	0.004	1.041	1.013	1.069	1950

* OR  =  Odds Ratio; CI  =  Confidence interval.

** With a planned treatment end or with treatment discontinuation for virological failure or adverse events.

# By univariate analysis baseline thrombocytes and GOT were also significant in GT3 in predicting SVR; in GT2 these variables were not significant. Since the APRI score which combines these two variables had a higher predictive value when compared with the two single variables only the APRI score was used for further analyses.